Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson single ascending-dose PK and safety study in paediatric cardiovascular patients undergoing myocardial perfusion MRI
2015-000500-26Phase 2
- Sponsor
- Rapidscan Pharma Solutions
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of regadenoson in cardiac morbidity (3 arms), sponsored by Rapidscan Pharma Solutions. Primary endpoint: Safety and tolerability endpoints.
02
Drugs
regadenoson
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on 2015-000500-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000500-26.